Stock DXB DIMERIX LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Dimerix Limited

Equities

DXB

AU000000DXB7

Market Closed - Australian S.E.
Other stock markets
 02:10:11 2024-05-03 EDT 		5-day change 1st Jan Change
0.36 AUD +7.46% Intraday chart for Dimerix Limited +12.50% +75.61%
05-01 Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication MT
04-22 Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication
MT
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter
MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target
MT
Dimerix Raises AU$20 Million for Kidney Disease Study
MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo
MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Dimerix Limited Announces Appointment of Mark Diamond as Director
CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%
MT
Dimerix Appoints Nonexecutive Chair
MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights
MT
Dimerix Appoints Medical Chief
MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer
CI
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand
AQ
Softer US Employment Data End Australian Shares' Three-Day Losing Streak
MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug
MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name
MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia
MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%
MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DXB Stock
  4. News Dimerix Limited